康弘药业KHN707片临床试验获批准

Core Viewpoint - Kanghong Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of KHN707 tablets, a novel drug for treating insomnia [1] Company Summary - Kanghong Pharmaceutical (002773) announced the receipt of a clinical trial approval notice for KHN707 tablets, which are a selective orexin receptor 2 (OX2R) antagonist [1] - KHN707 is classified as a Class 1 innovative chemical drug and is in tablet form [1] - Preliminary research indicates that KHN707 has good safety profiles and demonstrates effective therapeutic effects in insomnia models, suggesting a promising clinical application outlook [1]